Eli Lilly and Company posted a surge in fourth-quarter revenues on Thursday, fuelled by strong demand for its blockbuster diabetes and weight-loss drugs.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Eli Lilly has reported comprehensive outcomes from the Phase III SUMMIT trial of tirzepatide for individuals with heart failure with preserved ejection fraction (HFpEF) and obesity. The double ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly spooked the market with warnings of a small revenue slowdown in Q4 2024. Lilly nevertheless delivered good news about its prospects for sales growth in 2025. The company also dropped a ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...